Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma

BACKGROUND: Although patients with EGFR mutated lung adenocarcinoma benefit greatly from tyrosine kinase inhibitors (TKIs), they inevitably develop acquired resistance after an average of 10–14 months of continuous treatment. METHODS: We retrospectively analyzed the clinical and histopathological da...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jikai, Shao, Jinchen, Zhao, Ruiying, Li, Rong, Yu, Keke, Zhu, Lei, Zhang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754316/
https://www.ncbi.nlm.nih.gov/pubmed/29120087
http://dx.doi.org/10.1111/1759-7714.12549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754316/
https://www.ncbi.nlm.nih.gov/pubmed/29120087
http://dx.doi.org/10.1111/1759-7714.12549

Ejemplares similares